Turn Therapeutics publishes peer-reviewed GX-03 study in dermatology journal

Turn Therapeutics announced publication of a peer-reviewed study in the Journal of Dermatological Treatment demonstrating GX-03's efficacy in an IL-36-associated inflammatory dermatitis model with statistically significant disease severity reduction. The publication supports the company's Phase 2 development program for GX-03 in moderate-to-severe atopic dermatitis and represents the first in a planned series of scientific publications.